Gilead inks deal for cancer-beating antibody

Gilead will have an exclusive licence and will pay MacroGenics $60 million upfront | Deal includes tiered, double-digit royalties on worldwide net sales.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Gilead defeats immunity bid in hepatitis C patent case

7 March 2023 The University of Minnesota had raised three key issues on appeal | Sovereign immunity was at the heart of the years-long dispute.

Americas

Gilead must face pay-for-delay suit

23 August 2022 Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.

Big Pharma

Russian drugmakers bypass Gilead to unveil COVID-19 generic

4 February 2021 Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug remdesivir without the authorisation of the drug’s patent owner, Gilead Sciences.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Gilead inks deal for cancer-beating antibody

More on this story

Editor's picks

Editor's picks

More features